HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), PSMA inhibitors(Prostate-specific membrane antigen inhibitors)

+ [2]

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Lung Cancer

Inactive Indication-

Originator Organization

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Active Organization

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Clinical Trials associated with PSMA-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

NCT03198052 / RecruitingPhase 1IIT

CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial

The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR
-CAR-T cell immunotherapy on human cancers will firstly be tested.

Start Date01 Jul 2017

Sponsor / Collaborator

Second Affiliated Hospital of Guangzhou Medical University

[+2]

100 Clinical Results associated with PSMA-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

100 Translational Medicine associated with PSMA-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

100 Patents (Medical) associated with PSMA-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

Literatures (Medical) associated with PSMA-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

01 Oct 2024·Clinical Cancer Research

Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models

Article

Author: Nguyen, Phuong ; Fleming, Andrew ; Ross, Aaron B. ; Chockley, Peter J. ; Beckett, Alexandra ; Talbot, Lindsay J. ; Wang, Jian ; Gottschalk, Stephen ; Shepphard, Heather ; Chabot, Ashley ; DeRenzo, Christopher

AbstractPurpose:Clinical efficacy of chimeric antigen receptor (CAR) T cells against pediatric osteosarcoma (OS) has been limited. One strategy to improve efficacy may be to drive chemokine-mediated homing of CAR T cells to tumors. We sought to determine the primary chemokines secreted by OS and evaluate the efficacy of B7-H3.CAR T cells expressing the cognate receptors.Experimental Design:We developed a pipeline to identify chemokines secreted by OS by correlating RNA-seq data with chemokine protein detected in media from fresh surgical specimens. We identified CXCR2 and CXCR6 as promising receptors for enhancing CAR T-cell homing against OS. We evaluated the homing kinetics and efficiency of CXCR2- and CXCR6.T cells and homing, cytokine production, and antitumor activity of CXCR2- and CXCR6.B7-H3.CAR T cells in vitro and in vivo.Results:T cells transgenically expressing CXCR2 or CXCR6 exhibited ligand-specific enhanced migration over T cells modified with nonfunctional control receptors. Differential homing kinetics were observed, with CXCR2.T-cell homing quickly and plateauing early, whereas CXCR6.T cells took longer to home but achieved a similar plateau. When expressed in B7-H3.CAR T cells, CXCR2- and CXCR6 modification conferred enhanced homing toward OS in vitro and in vivo. CXCR2- and CXCR6-B7-H3.CAR-treated mice experienced prolonged survival in a metastatic model compared with B7-H3.CAR T-cell-treated mice.Conclusions:Our patient-based pipeline identified targets for chemokine receptor modification of CAR T cells targeting OS. CXCR2 and CXCR6 expression enhanced the homing and anti-OS activity of B7-H3.CAR T cells. These findings support clinical evaluation of CXCR-modified CAR T cells to improve adoptive cell therapy for patients with OS.

12 Sep 2024·Blood

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

Article

Author: Dey, Aonkon ; Cook, Daniella T. ; Wiggin, Hadley R. ; Berger, Trisha R. ; Horick, Nora K. ; Elder, Eva L. ; Schmidts, Andrea ; Leick, Mark B. ; Graham, Charlotte E. ; Katsis, Katelin ; Daley, Heather ; Ritz, Jerome ; Armant, Myriam ; Nikiforow, Sarah ; Lee, Won-Ho ; DiPersio, John F. ; Dolaher, Maria A. ; Nardi, Valentina ; Gallagher, Kathleen M. E. ; Preffer, Fred ; Wehrli, Marc ; Frigault, Matthew J. ; Scarfò, Irene ; Chen, Yi-Bin ; El-Jawahri, Areej ; Huang, Lu ; Bouffard, Amanda ; Maus, Marcela V. ; Parker, Aiyana L. ; Ritchey, Julie ; Haradhvala, Nicholas J. ; Chekmasova, Alena A.

AbstractWe report a first-in-human clinical trial using chimeric antigen receptor (CAR) T cells targeting CD37, an antigen highly expressed in B- and T-cell malignancies. Five patients with relapsed or refractory CD37+ lymphoid malignancies were enrolled and infused with autologous CAR-37 T cells. CAR-37 T cells expanded in the peripheral blood of all patients and, at peak, comprised >94% of the total lymphocytes in 4 of 5 patients. Tumor responses were observed in 4 of 5 patients with 3 complete responses, 1 mixed response, and 1 patient whose disease progressed rapidly and with relative loss of CD37 expression. Three patients experienced prolonged and severe pancytopenia, and in 2 of these patients, efforts to ablate CAR-37 T cells, which were engineered to coexpress truncated epidermal growth factor receptor, with cetuximab were unsuccessful. Hematopoiesis was restored in these 2 patients after allogeneic hematopoietic stem cell transplantation. No other severe, nonhematopoietic toxicities occurred. We investigated the mechanisms of profound pancytopenia and did not observe activation of CAR-37 T cells in response to hematopoietic stem cells in vitro or hematotoxicity in humanized models. Patients with pancytopenia had sustained high levels of interleukin-18 (IL-18) with low levels of IL-18 binding protein in their peripheral blood. IL-18 levels were significantly higher in CAR-37–treated patients than in both cytopenic and noncytopenic cohorts of CAR-19–treated patients. In conclusion, CAR-37 T cells exhibited antitumor activity, with significant CAR expansion and cytokine production. CAR-37 T cells may be an effective therapy in hematologic malignancies as a bridge to hematopoietic stem cell transplant. This trial was registered at www.ClinicalTrials.gov as #NCT04136275.

100 Deals associated with PSMA-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lung Cancer	Phase 1	CN	Guangdong Zhaotai InVivo Biomedicine Co. Ltd.	01 Jul 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

PSMA-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation